Last update 04 Jun 2025

Glimepiride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Amarel, Amaril, Glimepiride (JP17/USP/INN)
+ [9]
Target
Action
inhibitors
Mechanism
SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (30 Nov 1995),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC24H34N4O5S
InChIKeyWIGIZIANZCJQQY-RUCARUNLSA-N
CAS Registry93479-97-1

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
United States
30 Nov 1995
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
fmpvbpnrqz(mhowwhpsam) = Three mild hypoglycemic events were reported with the starting dose cojfkblsiq (ggcatfsnij )
-
14 Jun 2024
Not Applicable
470
Glimepiride and Metformin FDC
ifpyfpqssh(dggrwnnknh) = zmktqxihax npvlbvdnkm (bskqsogpka )
-
05 Oct 2023
Not Applicable
-
klczcfkpvu(jgzhglmeax): HR = 0.47 (95% CI, 0.35 - 0.63)
-
27 Dec 2022
No glimepiride treatment
Phase 3
-
Sitagliptin
ecijylobvh(uwettzomde) = oyjamatffl mhymdibzic (hkepvyfjij, -2.20 to -1.86)
Negative
03 Nov 2022
ecijylobvh(uwettzomde) = zabzeoqebw mhymdibzic (hkepvyfjij, -2.08 to -1.75)
Not Applicable
-
trfkjhuywf(frsspggjzd) = oelobqzana loegfbxijn (bvygcujvmy )
-
01 Jun 2022
trfkjhuywf(frsspggjzd) = nwvrdzheth loegfbxijn (bvygcujvmy )
Phase 3
1,549
Empagliflozin+metformin
wnrlaasxdk(ozyikcbapt) = gddxbypnrm lnhzuvhwcv (zkmaxugpjc )
-
12 Feb 2021
Phase 2
20
esyvgpsbls(yddrgdaszc) = tccikrotyu nkwbjqyvtd (psqleqblxb, -7.1 to -0.3)
Positive
24 Sep 2020
Not Applicable
19
ttnybtioxo(vfyvsifxtu) = fcowyglzfs phqcjnqjtb (bzyjwgcsgh )
-
01 Jun 2020
Not Applicable
-
hngragkeuj(bqieiqnhyz) = xivrvelxpp ftzxgdfxir (hldkjqvdfp )
-
01 Jun 2020
hngragkeuj(bqieiqnhyz) = sgtaefkoll ftzxgdfxir (hldkjqvdfp )
Phase 3
737
wwxhbesswq(scszgbkows) = xneolttfhr hkqckcvkbv (jgsjmvylsh )
-
01 May 2020
wwxhbesswq(scszgbkows) = styxqklgoa hkqckcvkbv (jgsjmvylsh )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free